<DOC>
	<DOC>NCT00955214</DOC>
	<brief_summary>The utilization of paclitaxel-eluting coronary stents in small vessel diseases is effective in reducing both repeat revascularization and major adverse cardiac events within two year follow-up. To evaluate the procedural, short and long term clinical outcomes of the Taxus Liberte™ Paclitaxel-Eluting Coronary Stent in small coronary arteries of ≤ 2.5 mm in the reference vessel diameter.</brief_summary>
	<brief_title>Small Coronary Artery Treated by TAXUS Liberté Registry in Japan</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina, Unstable</mesh_term>
	<mesh_term>Angina, Stable</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1. Age ≥20 years and are able to undergo CABG 2. Females who are not pregnant 3. Patients who present with angina symptoms or myocardial ischemia 4. Patients available for postprocedural observation and coronary angiography at 24 months 5. Patients who have signed patient informed consent 6. Lesion which is eligible for only one 2.5mm paclitaxeleluting stent 7. De novo lesion or nonstented restenosed lesion 1. Patients contraindicated for antiplatelet therapy or anticoagulant therapy 2. Patients with significant allergic reaction to contrast medium 3. Chronic total occlusion 4. Lesion with TIMI0 5. Lesion which is needed more than two stents 6. Patients with chronic renal failure (SCr&gt;3.0mg/dl)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>TAXUS Liberté</keyword>
	<keyword>Small coronary artery disease</keyword>
	<keyword>Paclitaxel-eluting stent</keyword>
</DOC>